Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Other · Spinal cord injury · Radiation
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- In trials, not approved
- ChEMBL max phase
- 2 / 4 (development scale, not regulatory approval)
- Synonyms
- Malol; Micromerol; NSC-167406; NSC-4060; Prunol; Ursolic acid; Urson
- Note
- Not recorded
Clinical trials 7
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
A Pilot Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)
Spinal Cord Injuries · Tetraplegia · Paraplegia · Muscle Loss · Atrophy, Muscular · Insulin Resistance
Enrolment: 10 · Results not recorded
Effect of Ursolic Acid of Loquat Extract on Function of Muscle in Human
Sarcopenia
Enrolment: 54 · Results not recorded
Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome
Metabolic Syndrome X
Enrolment: 24 · Results not recorded
An Open-Label Study Of Ursolic Acid For Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis
Enrolment: 0 · Results not recorded
Phase I Clinical Trial Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate
Prostate Cancer
Enrolment: 0 · Results not recorded
Phase I Clinical Trial Testing the Bioavailability of Phytonutrients, Curcumin and Ursolic Acid
Bioavailability of Phytonutrients
Enrolment: 18 · Results not recorded
Effects of Ursolic Acid-Standardized Apple Pomace Extract Formulated With Phospholipids on Muscle Strength and Physical Performance in Older Adults With Mild Sarcopenia
Sarcopenia
Enrolment: 105 · Results not recorded
Preclinical evidence 3
3 studies reported at therapy level; 3 evidence entries itemised.
MouseOtherInstitute of Cancer Research (ICR)MaleOral administration40 mg/kg body weight per dayPretreatment, given for 2 days before heat stress exposure
Model: Heat stress-induced acute lung injury: mice housed at normal temperature (23 plus or minus 1 degrees C) then exposed to high temperature (41 plus or minus 1 degrees C) for 2 h
Heat stress increased apoptosis, hydrogen peroxide production, serum TNF-alpha, IL-6 and IL-1beta, and lung malondialdehyde, lactate dehydrogenase and myeloperoxidase activity, while reducing superoxide dismutase and catalase activity. All these changes were significantly prevented by ursolic acid…
Extraction: extract · Supplied extraction confidence: 0.72. Machine-extracted fields require source verification.
MouseSpinal cord injuryUnspecifiedC57BL/6FemaleOralFirst dose 1 hour after spinal cord injury
Model: Spinal cord injury in mouse; specific injury method not stated in the abstract
Oral ursolic acid started 1 hour after injury and continued daily for 6 weeks improved regaining of motor function and axonal regrowth, decreased astrogliosis, lowered proinflammatory IL-6 and TNF-alpha in the acute phase, and activated MAPK and PI3K/Akt/mTOR signalling in the injured spinal cord.
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
MouseRadiationBALB/c25 mg/kg dailyAdministered 1 h after the acute irradiation or after each fractionated irradia…
Model: Acute whole-body irradiation with 5 Gy, or fractionated exposure with 0.5 Gy daily for 10 days to a total dose of 5 Gy
Acute 5 Gy irradiation caused deficits in contextual learning and memory and in novel object recognition and impaired subgranular zone neurogenesis, while fractionated exposure caused less loss of newly generated neurons and no behavioural deficit. Ursolic acid at 25 mg/kg daily for 30 days greatly…
Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.